Sun Pharmaceutical Industries Ltd. 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India

Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

Sun Pharma announces USFDA approval for generic Doxil®

Mumbai, February 05, 2013: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil®, Doxorubicin HCI Liposome Injection USP, 2mg/mL, packaged in 20 mg/10mL and 50 mg/25mL single-use vials.

This generic Doxorubicin HCl Liposome injection USP, 2 mg/mL is therapeutically equivalent to Doxil® Liposome Injection, 2 mg/mL of Janssen Research and Development, LLC.

Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

DOXIL® is a registered trademark of Janssen Products, LP (USA).

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Nimish Desai Mira Desai

Tel +91 22 6645 5645, Xtn 717 Tel +91 22 6645 5645, Xtn 606

 Tel Direct
 +91 22 66455717
 Tel Direct
 +91 22 66455606

 Mobile
 +91 98203 30182
 Mobile
 +91 98219 23797

 E mail
 nimish.desai@sunpharma.com
 E mail
 mira.desai@sunpharma.com